STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

IIOO NEW YORK AVENUE, N.W., SUITE 600 WASHINGTON, D.C. 20005-3934

www.skgf.com

PHONE: (202) 371-2600 FACSIMILE: (202) 371-2540

ROBERT GREENE STERNE EDWARD J. KESSLER JORGE A. GOLDSTEIN SAMUEL L. FOX DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHAELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE MICHAEL O. LEE

STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*

HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER

JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATITERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
MATTHEW M. CATLETT*
NATHAN K. KELLEY*
ALBERT J. FASULO II *
W. BRIAN EDGE*

KAREN R. MARKOWICZ** SUZANNE E. ZISKA** BRIAN J. DEL BUONO** ANDREA J. KAMAGE** NANCY J. LEITH** TARJA H. NAUKKARINEN**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

July 18, 2000

WRITER'S DIRECT NUMBER: (202) 371-2560 INTERNET ADDRESS: RESMOND@SKGF.COM

Commissioner for Patents Washington, D.C. 20231

via Hand Carry To: Examiner Monshipouri, M. Art Unit: 1652

Re:

U.S. Utility Patent Application

Appl. No. 09/064,057; Filed: April 22, 1998

For: Compositions and Methods for Reverse Transcription of Nucleic Acid Molecules

Inventors:

Gerard et al.

Our Ref:

0942.4330002/RWE/BJD

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Fifth Supplemental Information Disclosure Statement;
- 2. Form PTO-1449, 1 page, listing 2 documents;
- 3. One copy of each of the 2 cited documents on Form PTO-1449; and
- 4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents July 18, 2000 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants

Registration No. 32,893

RWE/BJD/D-K/jk Enclosures

P:\USERS\JKING\Biotech\BJD\0942-433-2transmltr-071800ids SKGF Rev. 4/27/00 mac

IN THE UNITED STATES PATENT AND TRADEMARK OFFIGECH 1600/2900

In re application of:

Gerard et al.

Appl. No. 09/064,057

Filed: April 22, 1998

For: Compositions and Methods for

Reverse Transcription of Nucleic

Acid Molecules

Art Unit:

1652

Examiner:

Monshipouri, M.

Atty. Docket: 0942.4330002/RWE/BJD

Fifth Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fifth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fourth Information Disclosure Statement filed on June 14, 2000 in connection with the above-captioned application.

Document No. AL2, Russian Patent No. 1490961 A1, is in Russian. In accordance with 37 C.F.R. §1.98(a)(3), Applicants' undersigned representative submits the relevance of Document No. AL2 can be ascertained by the content of the English-language abstract cited as Document No. AS23.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Fifth Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a first Office Action on the merits but before the mailing date of a Final Rejection or Notice of Allowance. The U.S. Patent and Trademark office is hereby authorized to charge the \$240 fee to our Deposit Account No. 19-0036.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicants

Registration No. 32,893

Date: July 18, 2000

1100 New York Avenue, N.W.

Suite 600 Washington, D.C. 20005-3934

(202) 371-2600